AR100168A1 - Proteínas agonistas de los receptores de trail de cadena simple - Google Patents

Proteínas agonistas de los receptores de trail de cadena simple

Info

Publication number
AR100168A1
AR100168A1 ARP150101224A ARP150101224A AR100168A1 AR 100168 A1 AR100168 A1 AR 100168A1 AR P150101224 A ARP150101224 A AR P150101224A AR P150101224 A ARP150101224 A AR P150101224A AR 100168 A1 AR100168 A1 AR 100168A1
Authority
AR
Argentina
Prior art keywords
agonist proteins
trail receptors
single chain
trail
proteins
Prior art date
Application number
ARP150101224A
Other languages
English (en)
Inventor
Hill Oliver
Gieffers Christian
Thiemann Meinolf
G Buchanan Fritz
C Phillips Darren
E Lappe Susan
Original Assignee
Apogenix Gmbh
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh, Abbvie Inc filed Critical Apogenix Gmbh
Publication of AR100168A1 publication Critical patent/AR100168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)

Abstract

Proteínas específicas que son agonistas de los receptores de TRAIL. Ácidos nucleicos que las codifican. Métodos para tratar una enfermedad o un trastorno asociado a los TRAIL en un sujeto. Las proteínas agonistas de los receptores de TRAIL que se proveen en la presente comprenden tres dominios de TRAIL solubles y un fragmento Fc. Las proteínas agonistas de los receptores de TRAIL no forman agregados de manera sustancial y son apropiadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.
ARP150101224A 2014-04-23 2015-04-23 Proteínas agonistas de los receptores de trail de cadena simple AR100168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
AR100168A1 true AR100168A1 (es) 2016-09-14

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101224A AR100168A1 (es) 2014-04-23 2015-04-23 Proteínas agonistas de los receptores de trail de cadena simple

Country Status (37)

Country Link
US (4) US9908927B2 (es)
EP (2) EP3134430B1 (es)
JP (2) JP6523331B2 (es)
KR (2) KR102079919B1 (es)
CN (2) CN106459221B (es)
AR (1) AR100168A1 (es)
AU (3) AU2015249649B2 (es)
BR (1) BR112016024515B1 (es)
CA (2) CA3184067A1 (es)
CL (1) CL2016002683A1 (es)
CR (1) CR20160516A (es)
CY (1) CY1120281T1 (es)
DK (1) DK3134430T3 (es)
DO (1) DOP2016000284A (es)
EC (1) ECSP16089579A (es)
ES (1) ES2672368T3 (es)
HR (1) HRP20180950T1 (es)
HU (1) HUE038914T2 (es)
IL (2) IL248244B (es)
LT (1) LT3134430T (es)
MA (2) MA39770A (es)
MX (2) MX2016013858A (es)
MY (1) MY181986A (es)
NO (1) NO2776305T3 (es)
PE (1) PE20170299A1 (es)
PH (1) PH12016502079B1 (es)
PL (1) PL3134430T3 (es)
PT (1) PT3134430T (es)
RS (1) RS57153B1 (es)
RU (1) RU2699285C2 (es)
SG (3) SG10201806465TA (es)
SI (1) SI3134430T1 (es)
TR (1) TR201806912T4 (es)
TW (2) TWI747178B (es)
UA (1) UA118286C2 (es)
UY (1) UY36095A (es)
WO (1) WO2015164588A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709355B (zh) * 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白
AU2016342420B2 (en) * 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
AU2016341402B2 (en) * 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins
AU2016341409B2 (en) 2015-10-23 2021-02-25 Apogenix Ag Single-chain CD27-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN109153711B (zh) * 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109641033A (zh) * 2016-06-13 2019-04-16 梅里麦克制药股份有限公司 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CA3106549A1 (en) * 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig l-asparaginase variants and methods of use
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
WO2022248662A1 (en) 2021-05-28 2022-12-01 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US8388962B2 (en) * 2005-04-15 2013-03-05 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating MCP-1/CCR2 associated diseases
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2176288B1 (en) 2007-07-10 2015-11-04 Apogenix GmbH Tnf superfamily collectin fusion proteins
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
EP2310509B1 (en) * 2008-07-21 2015-01-21 Apogenix GmbH Tnfsf single chain molecules
US20110287001A1 (en) 2008-09-22 2011-11-24 Tetralogic Pharmaceuticals Method of treatment
EP2379585A2 (en) * 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
CA2795325A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
US9764038B2 (en) * 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
CN104640876A (zh) * 2012-07-18 2015-05-20 阿珀吉尼科斯有限公司 包含CD95-Fc同种型的混合物的组合物

Also Published As

Publication number Publication date
CA2946402C (en) 2023-02-28
DK3134430T3 (en) 2018-05-22
HUE038914T2 (hu) 2018-12-28
UY36095A (es) 2015-10-30
PE20170299A1 (es) 2017-05-06
SG10201806465TA (en) 2018-08-30
PL3134430T3 (pl) 2018-08-31
IL272612A (en) 2020-03-31
TWI683825B (zh) 2020-02-01
SI3134430T1 (en) 2018-05-31
PH12016502079A1 (en) 2016-12-19
CL2016002683A1 (es) 2017-07-07
UA118286C2 (uk) 2018-12-26
TW202024123A (zh) 2020-07-01
AU2015249649A1 (en) 2016-11-10
TWI747178B (zh) 2021-11-21
RU2016145608A3 (es) 2018-12-26
US20210040178A1 (en) 2021-02-11
US20180222962A1 (en) 2018-08-09
TW201620928A (zh) 2016-06-16
IL248244B (en) 2020-03-31
CN106459221B (zh) 2020-09-01
MX2016013858A (es) 2017-08-02
AU2018271369A1 (en) 2018-12-20
PT3134430T (pt) 2018-04-20
JP6714751B2 (ja) 2020-06-24
MY181986A (en) 2021-01-18
WO2015164588A1 (en) 2015-10-29
EP3134430A1 (en) 2017-03-01
CR20160516A (es) 2017-05-10
CY1120281T1 (el) 2019-07-10
KR20190135546A (ko) 2019-12-06
PH12016502079B1 (en) 2016-12-19
EP3366699A1 (en) 2018-08-29
SG11201608767XA (en) 2016-11-29
MX2019013587A (es) 2020-01-13
US20150337027A1 (en) 2015-11-26
MA39770A (fr) 2015-10-29
IL248244A0 (en) 2016-11-30
SG10202111785VA (en) 2021-12-30
HRP20180950T1 (hr) 2018-08-10
JP2019162114A (ja) 2019-09-26
MA45069A (fr) 2019-04-03
BR112016024515B1 (pt) 2020-03-31
TR201806912T4 (tr) 2018-06-21
NZ725476A (en) 2023-09-29
JP2017513503A (ja) 2017-06-01
RU2699285C2 (ru) 2019-09-04
US9908927B2 (en) 2018-03-06
AU2020202247A1 (en) 2020-04-23
RU2016145608A (ru) 2018-05-28
JP6523331B2 (ja) 2019-05-29
ECSP16089579A (es) 2018-05-31
NO2776305T3 (es) 2018-01-27
LT3134430T (lt) 2018-05-10
KR20170012257A (ko) 2017-02-02
AU2015249649B2 (en) 2018-10-04
US20240174731A1 (en) 2024-05-30
ES2672368T3 (es) 2018-06-14
BR112016024515A2 (pt) 2017-10-10
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
KR102079919B1 (ko) 2020-02-24
CA2946402A1 (en) 2015-10-29
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
RS57153B1 (sr) 2018-07-31
DOP2016000284A (es) 2017-02-15
EP3134430B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
CL2016002683A1 (es) Proteínas agonistas de los receptores de trail de cadena simple
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112016003394A2 (pt) usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica
CO2017003005A2 (es) Anticuerpos anti-mfi2
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112017023131A2 (pt) anticorpos anti- fcrn
EA201790356A1 (ru) Метил- и трифторметилзамещенные пирролопиридиновые модуляторы rorc2 и способы их применения
BR112016010822A2 (pt) anticorpos específicos para fcrn
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
EA201692395A1 (ru) Новые соединения

Legal Events

Date Code Title Description
FG Grant, registration